Isoindolinone and indazole compounds for the degradation of EGFR

MYPI2026003133A0Undetermined Publication Date: 2021-06-20C4 THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2026003133
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-12-20
Filing Date
2020-12-18
Publication Date
2021-06-20
Patent Text Reader

Abstract

ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR ABSTRACT The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers. [No Available Figure]
Need to check novelty before this filing date? Find Prior Art